Researchers conducting a clinical trial of immunotherapy drugs for people with head and neck squamous cell carcinomas (HNSCCs) found that patients responded better to a combination of two immunotherapies than patients who received just one immunotherapy drug.
Asklepios shows resilience in 2023 financial year – Biotech Investments
EQS-News: Asklepios Kliniken / Key word(s): Annual Report Asklepios Group: Asklepios shows resilience in 2023 financial year 25.04.2024 / 10:00 CET/CEST The issuer is solely